Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema
Status:
Completed
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
Intravitreal ranibizumab alone was Compared to adding dexamethasone to ranibizumab regarding
central macular thickness, the visual acuity and the number of intravitreal injections needed
to achieve the same effect on CMT and BCVA at the end of the 6 months duration of the study.
Any significant change in final IOP, compared to baseline, in either group is reported.